Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

Irene M. Ghobrial, M.D., Nikhil Munshi, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc, Marybeth Nelson, PA, Amy Sam, Kelly O’Connor, Brianna Harris, Diane Warren, Akari M. Dollard, Jacob Laubach, MD, Ravi Vij, MD, Erica Campagnaro, MD, Ann Birner, Virginia Dixon-Lipscomb, Kenneth C. Anderson, Paul G. Richardson

Blood (2008) 112 (11): 3696.

https://doi.org/10.1182/blood.V112.11.3696.3696

Published: 2008

Journal Articles

Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).

Irene M. Ghobrial, M.D., Xavier Leleu, MD, PhD, Nancy Rubin, MD, Wanling Xie, Fangxin Hong, Stacey Chuma, RN, Renee Leduc, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Diane Warren, Peter Sportelli, Steven P. Treon, MD, PhD, Edie Weller, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2008) 112 (11): 1010.

https://doi.org/10.1182/blood.V112.11.1010.1010

Published: 2008

Journal Articles

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

Irene M. Ghobrial, M.D., Stacey Chuma, RN, Amy Sam, Renee Leduc, Marybeth Nelson, PA, Kelly O’Connor, Brianna Harris, Jacob Soumerai, Diane Warren, Eric Jacobsen, MD, Daniel DeAngelo, MD, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Thomas E. Witzig, MD, Steven P. Treon, MD, PhD

Blood (2008) 112 (11): 1011.

https://doi.org/10.1182/blood.V112.11.1011.1011

Published: 2008

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, M.D., Jeffrey Matous, MD, Swaminathan Padmanabhan, MD, Ashraf Badros, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc1, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, MD, Steven P. Treon, MD, PhD, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 832.

https://doi.org/10.1182/blood.V112.11.832.832

Published: 2008

Journal Articles

Imatinib Mesylate (Gleevec®) Produces Responses in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia.

Jacob D. Soumerai, Kelly E. O’Connor, Leukothea M. Ioakimidis, MS, Christopher J. Patterson, Bryan T. Ciccarelli, Renee Leduc, Zachary R. Hunter, Marybeth Nelson, PA-C, Aldo M. Roccaro, MD, Xavier Leleu, MD, Evdoxia Hatjiharissi, MD, Sophia Adamia, PhD, Lian Xu, Irene M. Ghobrial, MD, Steven P. Treon, MD, PhD

Blood (2007) 110 (11): 2575.

https://doi.org/10.1182/blood.V110.11.2575.2575

Published: 2007

Journal Articles

Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).

Xavier Leleu, MD, Evdoxia Hatjiharissi, MD, Aldo M. Roccaro, MD, Anne-Sophie Moreau, MD, Renee Leduc, Marybeth Nelson, Mena Farag, Steven P. Treon, MD, Irene M. Ghobrial, MD

Blood (2007) 110 (11): 1486.

https://doi.org/10.1182/blood.V110.11.1486.1486

Published: 2007

Journal Articles

Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial, Xavier Leleu, Nancy Rubin, Marybeth Nelson, Renee Leduc, Diane Warren, Jana Allen, Sue Lovecchio, Jacob Soumerai, Peter Sportelli, Robert Birch, Craig Henderson, Steven P. Treon, Paul Richardson, Kenneth C. Anderson

Blood (2007) 110 (11): 4493.

https://doi.org/10.1182/blood.V110.11.4493.4493

Published: 2007

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial, Swaminathan Padmanabhan, Ashraf Badros, Marybeth Nelson, Renee Leduc, Xavier Leleu, Diane Warren, Jacob Soumerai, Ann Birner, Robert Schlossman, Nikhil Munshi, Paul Richardson, Steven P. Treon, Kenneth C. Anderson

Blood (2007) 110 (11): 4494.

https://doi.org/10.1182/blood.V110.11.4494.4494

Published: 2007

Journal Articles

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial, Renee Leduc, Marybeth Nelson, Xavier Leleu, Eric Jacobsen, Ann LaCasce, Daniel DeAngelo, David Fisher, Jennifer R. Brown, Robert Schlossman, Diane Warren, Jacob Soumerai, Kelly O’Connor, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson, Thomas E. Witzig, Steven P. Treon

Blood (2007) 110 (11): 4496.

https://doi.org/10.1182/blood.V110.11.4496.4496

Published: 2007

NARROW

Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Imatinib Mesylate (Gleevec®) Produces Responses in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia.

Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).

Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only